{"id":"cbc2b9a2-4f76-5626-9ce9-bf82c2c8dc31","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-bfragilis-colonisation","predicate":"impairs","statement":"High-fat-diet mice colonised with B. fragilis were predisposed to more severe glucose intolerance, and the metabolic benefits of metformin were abrogated.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"c46bc012-23c1-57a3-9354-464a1f7606b4","mechanism_event_label":"Putting the bacterium back removed the benefit, which is what makes this more than a correlation.","subject":{"id":"b4f38d31-8e45-5633-bd30-98cb16e08232","slug":"bacteroides-fragilis","display_name":"Bacteroides fragilis","entity_type_key":"organism"},"object":{"id":"b0fcea7a-0388-5f63-b7bb-38817cd5924f","slug":"glucose-tolerance","display_name":"Glucose tolerance","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c46bc012-23c1-57a3-9354-464a1f7606b4","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-bfragilis-colonisation-event","event_type":"biochemical_relationship","label":"Putting the bacterium back removed the benefit, which is what makes this more than a correlation.","description":"High-fat-diet mice colonised with B. fragilis were predisposed to more severe glucose intolerance, and the metabolic benefits of metformin were abrogated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"role":"blocked_actor","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b4f38d31-8e45-5633-bd30-98cb16e08232","slug":"bacteroides-fragilis","display_name":"Bacteroides fragilis","entity_type_key":"organism"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"b0fcea7a-0388-5f63-b7bb-38817cd5924f","slug":"glucose-tolerance","display_name":"Glucose tolerance","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/metformin-research/30397356.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0dbf1f5a262207595ede745deeb9fc79ba7732dc4d6af6b5c9d654712d79c1cf\", \"start_char\": 0, \"end_char\": 1433, \"text_sha256\": \"0dbf1f5a262207595ede745deeb9fc79ba7732dc4d6af6b5c9d654712d79c1cf\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Metagenomic and metabolomic analysis in newly diagnosed type 2 diabetes with mouse colonisation experiments","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Three days of metformin in treatment-naive people; B. fragilis colonisation in high-fat-diet mice","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A three-day human exposure with a mouse causal test. GUDCA is identified as an intestinal FXR antagonist; whole-body FXR biology is not claimed.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"metformin","display_name":"Metformin","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human and mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Putting the bacterium back removed the benefit, which is what makes this more than a correlation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[metformin-p30397356] Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. (2018). https://pubmed.ncbi.nlm.nih.gov/30397356/ DOI: 10.1038/s41591-018-0222-4","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Gut lumen and intestinal epithelium","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6823ea7b-4372-5758-885a-b12422199bab","evidence_kind":"source_excerpt","locator":"Lines 892-903","start_line":892,"end_line":903,"excerpt":"### metformin-bfragilis-colonisation\nHigh-fat-diet mice colonised with B. fragilis were predisposed to more severe glucose intolerance, and the metabolic benefits of metformin were abrogated.\nCondition category: normal\nnutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.\nplain_language: Putting the bacterium back removed the benefit, which is what makes this more than a correlation.\norganism: Human and mouse\ntissue_or_cell_type: Gut lumen and intestinal epithelium\nexperimental_model: Metagenomic and metabolomic analysis in newly diagnosed type 2 diabetes with mouse colonisation experiments\nlimitations: A three-day human exposure with a mouse causal test. GUDCA is identified as an intestinal FXR antagonist; whole-body FXR biology is not claimed.\nexposure: Three days of metformin in treatment-naive people; B. fragilis colonisation in high-fat-diet mice\nevidence_span: {\"source_cache\": \"artifacts/metformin-research/30397356.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0dbf1f5a262207595ede745deeb9fc79ba7732dc4d6af6b5c9d654712d79c1cf\", \"start_char\": 0, \"end_char\": 1433, \"text_sha256\": \"0dbf1f5a262207595ede745deeb9fc79ba7732dc4d6af6b5c9d654712d79c1cf\"}\n[metformin-p30397356] Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. (2018). https://pubmed.ncbi.nlm.nih.gov/30397356/ DOI: 10.1038/s41591-018-0222-4","model_system":"Metagenomic and metabolomic analysis in newly diagnosed type 2 diabetes with mouse colonisation experiments","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [metformin-p30397356] Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. (2018). https://pubmed.ncbi.nlm.nih.gov/30397356/ DOI: 10.1038/s41591-018-0222-4","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d0474bd9-7cfd-5695-a152-12f3633a6813","stable_key":"import-8b3cf083-ea9c-54f5-b42b-bf1fef5b2978","title":"Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0b51d0759aeeb88ac5b3a6277245a196b2bb024d7c32ec89379ed428fb06bfb5","revision_id":"0405c75e-f06e-5af7-a642-1777802f6004","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}